Resonance Health (ASX:RHT) Growth Rank : 0 (As of May. 26, 2024)

View and export this data going back to 1987. Start your Free Trial

What is Resonance Health Growth Rank?

Resonance Health has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Resonance Health Growth Rank Related Terms

Thank you for viewing the detailed overview of Resonance Health's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Resonance Health (ASX:RHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Resonance Health Ltd (ASX:RHT) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

141 Burswood Road, Level 1, Burswood, WA, AUS, 6100

Website

https://www.resonancehealth.com

Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, and HepaFat-Scan. The company's operating segment includes Services; Research and Development and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of its revenue from North America and Europe-Middle-East-Africa (EMEA) and also has a presence in Asia/Pacific.

Resonance Health (ASX:RHT) Headlines

No Headlines